Lili Han
Papers
2
Total Citations
9
H-Index
2
About
Dr. Lili Han is a pioneering surgical oncologist whose research focuses on de-escalation treatment strategies for HPV-associated oropharyngeal cancer (OPC). Her major contributions center on integrating neoadjuvant immunochemotherapy with transoral robotic surgery (TORS) to reduce treatment toxicity while maintaining excellent oncologic outcomes. In her landmark single-arm, phase II trial (2024), Dr. Han demonstrated that combining the anti-PD-1 agent sintilimab with platinum-doublet chemotherapy before TORS yields high major pathological response rates in HPV-positive resectable OPC. This work was expanded in a two-centre phase 2 trial (2025), which confirmed the safety and efficacy of this approach, achieving significant pathological responses while preserving organ function. Though recently published, these studies have already garnered 5 and 4 citations respectively, reflecting their immediate impact on the field. Dr. Han’s research addresses a critical unmet need—balancing cure rates with quality of life—by offering a less morbid alternative to traditional chemoradiation. Her work positions her at the forefront of surgical de-escalation trials, with implications for redefining standard-of-care in HPV-driven head and neck cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2